Delivery Order SPE2DB24D1021-SPE2DB25FFAJG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,660.99 to AmerisourceBergen Drug Corp for Shingrix vial kits. The contract is firm fixed price with no set-aside designation and has an ultimate completion date of September 17, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement and holds the place of performance for this award at its corporate office location. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,139.18 to AmerisourceBergen Drug Corp for Shingrix vial kits on June 2, 2025, with an ultimate completion date of June 3, 2025. This firm fixed-price contract, issued without a set-aside designation, represents a competitive award to the prime contractor for vaccine supply. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,139.18 for Shingrix vial kits, with an ultimate completion date of July 15, 2025. This firm fixed-price contract was competitively awarded without a set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $3,874.49 to AmerisourceBergen Drug Corp for Shingrix vial kits on August 28, 2025, with a completion date of August 29, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award based on merit. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits valued at $1,139.18, with an ultimate completion date of August 25, 2025. This competitive, firm fixed price delivery order was issued on August 22, 2025, with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across the Department of Defense and other...
- The Defense Logistics Agency awarded a delivery order valued at $3,417.54 to AmerisourceBergen Drug Corp for Shingrix vial kits on July 28, 2025, with completion expected by July 29, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location. Shingrix is a recombinant zoster vaccine used...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits valued at $17,282.29 under a firm fixed-price contract. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and represents a non-competitive set-aside delivery order. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the company's existing...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order for Shingrix vial kits valued at $10,003.60 by the Defense Logistics Agency on September 3, 2025. The contract is a firm fixed price delivery order with an ultimate completion date of September 4, 2025, and operates under a competitive, non-set-aside procurement. This award is a child contract under AmerisourceBergen's significant Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,139.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits, with a completion deadline of July 14, 2025. This competitively awarded contract, issued on July 11, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $5,695.90 to AmerisourceBergen Drug Corp for Shingrix vial kits on August 25, 2025, with completion targeted for August 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Shingrix is a recombinant zoster vaccine administered to prevent herpes zoster (shingles) and is a critical...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FFAJGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,695.90 to AmerisourceBergen Drug Corp for Shingrix vial kits on September 8, 2025, with an ultimate completion date of September 9, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp will perform the delivery from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor headquartered in Pennsylvania, AmerisourceBergen Drug Corp supplies critical pharmaceutical products and medical commodities to support Defense Department healthcare systems, including the Defense Health Agency and U.S. Coast Guard. Shingrix, a recombinant zoster vaccine, represents a routine medical supply requirement within the company's extensive portfolio of vaccines, specialty medications, and medical supplies delivered through the DLA Medical Supply Chain. The competitive award demonstrates the company's continued capability to meet federal procurement requirements for pharmaceutical distribution and supports military readiness through reliable vaccine supply chain management.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.7k | 9/8/25 |